Direct-acting antiviral agents
Long term follow up of HCV infected kidney transplant recipients receiving direct acting antiviral agents: a single center experience in China
... of direct-acting antiviral agents (DAAs), which are oral, IFN-free molecules that target HCV proteins, have taken the HCV treatment into a new ...
6
Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus
... Background: Direct-acting antiviral agents (DAAs) permit the use of interferon (IFN)-free regimens to treat hepatitis C (HCV) in patients with chronic kidney disease (CKD) on hemo- dialysis ...
8
New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents
... 50 direct-acting antiviral agents (DAA) designed to target viral-encoded proteins essential in the HCV life cycle are currently under ...
13
<p>Successful Treatment of Hepatitis C Virus Infection Using Direct-Acting Antiviral Agents (DAAs) in Adolescents with Kidney Transplantation: A Case Series</p>
... Moreover, direct-acting antiviral agents (DAAs) are recommended for treating chronic HCV-infected KTR because of the poor ef fi cacy and higher risk of acute allograft rejection associated with ...
8
Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis
... Background: Direct-acting antivirals (DAAs) are known to improve tolerability and have higher efficacy and shorter treatment durations compared with conventional interferon (IFN)-based treatments for ...
8
Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents
... The APRI and FIB-4 index have been used to evaluate fibrosis regression after antiviral therapy [13, 14]; how- ever, Kim et al. reported that these two indices were not suitable for evaluating improvement of liver ...
9
Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents
... Sanger sequencing of patient-derived NS5A and NS5B regions was performed on all available samples, while ultradeep pyrosequencing (UDPS) of NS5A and NS5B regions was performed only on [r] ...
11
Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China
... To our knowledge, this study is the first to report the prevalence of RASs in western Chinese chronic HCV 1b patients. Moreover, the latest and most comprehensive panel of clinically relevant RASs was included to analyze ...
16
Direct acting antiviral agents in the therapy of hepatitis C virus related mixed cryoglobulinaemia: a single centre experience
... In terms of clinical manifestations, we observed regres- sion of Meltzer’s triad of symptoms (cryoglobulinaemic glomerulonephritis and peripheral neuropathy), which ei- ther were no longer present or were remarkably ...
10
A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents
... study, the univariate analysis revealed a significant positive correlation of FGF21 with serum albumin (r= 0.3, P≤ 0.002), and the multiple linear regression analysis documented the mean serum albumin level as ...
8
Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents
... 15% to expenses for pharmaceuticals and other medi- cines. The cost of CHC are largely defined by the rising expenses for pensions due to increase in RWA. However, there was a strong rise in cost of drug therapy in 2012 ...
8
Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
... Recently, direct antiviral agents such as protease inhibitors, polymerase inhibitors, or NS5A inhibitors have been used to augment PEGylated interferon and ribavirin, resulting in better efficacy, ...
17
<p>Lower Rates Of Naturally Occurring Resistance-Associated Substitutions (RASs) In Hepatitis C Virus (HCV)-Infected Chronic Kidney Disease (CKD) Patients Than In HCV-Infected Patients With Only Liver Disease</p>
... Hepatitis C virus (HCV) is a global health problem and affects 185 million people worldwide. 1 HCV therapy has been revolutionized with the recent introduction of direct-acting antiviral ...
6
<p>Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed</p>
... therapies. Direct-acting antiviral agents (DAAs) have achieved high eradication rates with an excellent safety pro- fi le since revolutionized the management of HCV ...
8
<p>Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection – A Real-World Cohort Study</p>
... 8 Direct-acting antiviral agents (DAAs) can further increase the sustained virological response (SVR) rate even to over 90% and have become the new standard for the treatment of ...treatment, ...
8
EVALUATION OF THE EFFICACY AND SAFETY OF COMPLEX THERAPY OF ACUTE RESPIRATORY DISEASES OF ADENOVIRAL ETIOLOGY IN YOUNG PEOPLE
... of direct-acting antiviral agents (oseltamivir and umifenovir) and Kagocel, an interferon inducer that stimulates the patient's innate immunity, is more effective than monotherapy with a ...
10
Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017
... Treatment of chronic hepatitis C virus (HCV) infection has been subject to vivid changes in the last few years with the introduction of direct-acting antiviral agents (DAAs) [1]. The ambition ...
10
Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
... HCV direct-acting antiviral (DAA) agents are associ- ated with a sustained virological response (SVR) rate of over 90% regardless of the genotype, including in HIV- infected patients [7, ...
11
Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
... Approximately 2.75 million people worldwide have HIV- HCV co-infection and 2.6 million have HBV-HCV co- infection [64]. HIV infection accelerates the progression of HCV to cirrhosis [65], but HIV's contribution to stea- ...
7
Effectiveness of Sofosbuvir regime in Hepatitis C virus infection in hemodialysis Pakistani patients: Single Centre Study
... the direct-acting antivirals have been revolutionary in the treatment of hepatitis C, and sofosbuvir (SOF) is the backbone of most modern treatment strategies with better prognosis of the infection and ...
5